Piromelatine
Piromelatine (Neu-P11) is a multimodal sleep drug under development by Neurim Pharmaceuticals.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Piromelatine (Neu-P11) is a multimodal sleep drug under development by Neurim Pharmaceuticals. It is an agonist at melatonin MT 1 /MT 2 and serotonin 5-HT 1A /5-HT 1D receptors. Neurim is conducting a phase II randomized, placebo controlled trial of cognitive and sleep effects in Alzheimer's disease.
Results of a phase II trial on insomnia in 120 adults were announced in 2013, finding piromelatine 20/50 mg improved sleep over 4 weeks vs placebo. Phase 1A/1B studies in 2011, showed safe dose-dependent improvement in sleep. Pre-clinical studies showed antinociceptive antihypertensive and cognitive benefits in rat disease models of pain, hypertension, and Alzheimer's disease.
Antidepressant and anti-anxiety effects were also demonstrated in animal models.
Piromelatine (Neu-P11) is a multimodal sleep drug under development by Neurim Pharmaceuticals. It is an agonist at melatonin MT 1 /MT 2 and serotonin 5-HT 1A /5-HT 1D receptors. Neurim is conducting a phase II randomized, placebo controlled trial of cognitive and sleep effects in Alzheimer's disease.
Results of a phase II trial on insomnia in 120 adults were announced in 2013, finding piromelatine 20/50 mg improved sleep over 4 weeks vs placebo. Phase 1A/1B studies in 2011, showed safe dose-dependent improvement in sleep. Pre-clinical studies showed antinociceptive antihypertensive and cognitive benefits in rat disease models of pain, hypertension, and Alzheimer's disease.
Antidepressant and anti-anxiety effects were also demonstrated in animal models.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1328703369 under CC BY-SA 4.0; modifications have been made.